Substituted-1-phthalazinamines as vr-1 antagonists
申请人:Blurton Peter
公开号:US20060229307A1
公开(公告)日:2006-10-12
The present invention provides a compound of formula (I): in which Ar and R
1
are phenyl or a heteroaromatic group, R
2
is generally hydrogen, R
3
is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation.
SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS
申请人:MERCK SHARP & DOHME LTD.
公开号:EP1625119A1
公开(公告)日:2006-02-15
US7329659B2
申请人:——
公开号:US7329659B2
公开(公告)日:2008-02-12
[EN] SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS<br/>[FR] 1-PHTALAZINAMINES SUBSTITUEES EN TANT QU'ANTAGONISTES DE VR-1
申请人:MERCK SHARP & DOHME
公开号:WO2004099177A1
公开(公告)日:2004-11-18
The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation.